Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,750 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression Severe Clear all
Completed No phase listed Observational

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT05841030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

Safety Study of F2695 SR in Major Depressive Disorder

NCT01034267
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
F2695 SR
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
68
States / cities
Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional

Nicotinic Receptor Augmentation of SSRI Antidepressants

NCT00319319
View directory record Official record
Conditions
Depressive Disorder
Interventions
Mecamylamine hydrochloride (Inversine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 17, 2026, 7:20 AM EDT
Enrolling by invitation Phase 4 Interventional

Precision Care for Major Depressive Disorder

NCT06580041
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Major
Interventions
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
Drug · Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

NCT00731653
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Combination Product: BCI-024 + BCI-049
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250601
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Results available

Org 24448 to Treat Major Depression

NCT00113022
View directory record Official record
Conditions
Depression
Interventions
Org 24448, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder

NCT04504253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine monohydrate, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

NCT06057012
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
BRII-296, Depo Medrol
Drug
Lead sponsor
Brii Biosciences Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
11
States / cities
Sherman Oaks, California • Torrance, California • Boynton Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 17, 2026, 7:20 AM EDT
Withdrawn Not applicable Interventional

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

NCT03804619
View directory record Official record
Conditions
Opiate Dependence, Suicidal Ideation, Depression, Opioid Use, Opioid-Related Disorders, Opioid-use Disorder, Major Depressive Disorder
Interventions
Accelerated intermittent theta-burst stimulation (aiTBS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Lexapro and Pramipexole and to Treat Major Depression

NCT00086307
View directory record Official record
Conditions
Major Depression
Interventions
Pramipexole, Escitalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness

NCT03062267
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Mobile Interventionist
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional

Risperidone vs. Paroxetine for Panic Attacks

NCT00206765
View directory record Official record
Conditions
Major Depressive Disorder With Panic Attacks, Panic Disorder
Interventions
Risperidone, Paroxetine
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 17, 2026, 7:20 AM EDT
Recruiting Not applicable Interventional

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

NCT05573074
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Photobiomodulator, Sham
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Sleep To Reduce Incident Depression Effectively

NCT03322774
View directory record Official record
Conditions
Insomnia, Primary, Major Depressive Disorder, Rumination
Interventions
digital Cognitive Behavioral Therapy for Insomnia, face-to-face Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education Control
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 17, 2026, 7:20 AM EDT
Recruiting Not applicable Interventional

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT06982820
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Prism Training
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
22 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

A Randomized Controlled Trial of PCIT-ED for Preschool Depression

NCT02076425
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
PCIT-ED
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
36 Months to 83 Months
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 17, 2026, 7:20 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

NCT03065335
View directory record Official record
Conditions
Healthy Volunteer, Major Depressive Disorder, Depression
Interventions
Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
Drug · Other · Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors

NCT01652768
View directory record Official record
Conditions
Malignant Brain Tumors
Interventions
Research Questionnaires, Palliative Care Team, Educational Information Session for Patients and Caregivers, Contact every 2 weeks, Follow-up Surgical Visit Session, Medical and/or Radiation Oncology Appointment Session
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance

NCT02190968
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, in Remission, Depressive Symptoms
Interventions
Usual Depression Care, Mindful Mood Balance
Behavioral
Lead sponsor
University of Toronto
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Ketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

NCT00073203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
R228060, Placebo and Paroxetine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2009 · Synced Oct 17, 2026, 7:20 AM EDT